The earnings call conveyed a cautiously optimistic outlook, with significant progress in clinical trials and strong interest from transplant centers and pharma partners. However, challenges remain in managing revenue volatility and cash burn.

Company Guidance -

Q2 2025

During OncoCyte's First Quarter 2025 Results call, the company outlined key guidance and metrics for the fiscal year. Their primary objectives include finalizing the clinical assay and trial design, completing a clinical trial to submit a data package to the FDA by the end of 2025, and ramping up revenue in 2026 by signing transplant centers for their research use-only kit. OncoCyte aims to have 20 sites trained on their GraftAssure workflow by the end of 2025, expanding from the 10 sites currently using their RUO assay across the U.S., Germany, U.K., Switzerland, Austria, and Southeast Asia. The company achieved central IRB approval for their clinical trial and anticipates participation from at least 3 of the top 10 U.S. transplant centers. Additionally, OncoCyte reported Q1 pharma services revenue of $2.1 million, with gross margins at 62%, and ended the quarter with nearly $33 million in cash. The company targets a cash burn rate of approximately $6 million per quarter until their commercial launch next year.

Central IRB Approval for Clinical Trial

OncoCyte finalized their clinical trial design and received central IRB approval, marking a key milestone in safety and ethics review for their trial.

Strong Revenue from Pharma Services

Pharma services revenue of $2.1 million exceeded expectations, with gross margins of 62%. A large order late in the quarter enabled invoicing of $1.4 million.

Interest from Top Transplant Centers

OncoCyte expects to welcome at least 3 of the top 10 U.S. transplant centers as clinical trial participants, representing nearly 10% of U.S. transplant volumes.

Global Expansion of RUO Sites

10 sites are currently running OncoCyte's RUO assay in the U.S., Germany, U.K., Switzerland, Austria, and Southeast Asia.

Digital PCR Differentiation

OncoCyte is proving the value of digital PCR as a technology differentiator, offering simpler, faster, and cost-effective solutions compared to NGS.

Positive Feedback on DetermaIO

DetermaIO is showing promise in the drug rescue category, with potential partners expressing admiration for the results.

Strong Cash Position

OncoCyte concluded the first quarter with nearly $33 million in cash, including restricted cash to be accessed later this year.

Insight Molecular Diagnostics (IMDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.23 / -	-0.385	―	―	―
May 12, 2025	2025 (Q1)	-0.24 / -0.19	-0.618	69.58% (+0.43)	―
Mar 24, 2025	2024 (Q4)	-0.40 / -1.93	-2.27	14.98% (+0.34)	―
Nov 12, 2024	2024 (Q3)	-0.44 / -0.40	-0.81	50.37% (+0.41)	―
Aug 08, 2024	2024 (Q2)	-0.56 / -0.39	-1.07	64.02% (+0.69)	―
May 15, 2024	2024 (Q1)	- / -	0.4	―	―
Apr 12, 2024	2023 (Q4)	-0.67 / -0.62	0.4	-254.50% (-1.02)	―
Nov 09, 2023	2023 (Q3)	-1.01 / -0.81	-1.692	52.13% (+0.88)	―
Aug 10, 2023	2023 (Q2)	-1.30 / -1.07	-1.4	23.57% (+0.33)	―
May 11, 2023	2023 (Q1)	- / -	-2.2	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2025	$2.81	$2.77	-1.42%
Mar 24, 2025	$3.33	$3.04	-8.71%
Nov 12, 2024	$3.00	$2.94	-2.00%
Aug 08, 2024	$3.08	$3.12	+1.30%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Insight Molecular Diagnostics Inc. (IMDX) report earnings?

Insight Molecular Diagnostics Inc. (IMDX) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is Insight Molecular Diagnostics Inc. (IMDX) earnings time?

Insight Molecular Diagnostics Inc. (IMDX) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMDX EPS forecast?

IMDX EPS forecast for the fiscal quarter 2025 (Q2) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing